-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant c

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a bio

Top Wall Street analysts changed outlook on several top stocks. See all changes on analyst ratings p

Wall Street analysts change outlook on top stocks, including LIME, CIFR, BSP, DMRA, and ITG. Check a

US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ:

BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a bio

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a bio

Damora Therapeutics is focused on mutant-CALR blood diseases, with DMR-001 as its lead asset. They h

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR

BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biot

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ: DMRA - Get Free Report) have earned an ave

Does Galecto, Inc. (DMRA) have what it takes to be a top stock pick for momentum investors? Let's fi

The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in DA

BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a bi

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ: DMRA - Get Free Report) have earned an ave

-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -

-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datase